Clinical trials: PHN - Post-Herpetic Neuritis, open to volunteers
PHN - Post-Herpetic Neuritis
A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia.
APC101 is developed to provide continuous lidocaine administration over 24 hours and is safe when administered to intact skin. Dispensing from a metered-dose spray pump, APC101 provides once or twice daily flexible dosing options…
- Trial name
- PHN (NCT07599800)
- Testing
- APC101, Control
- Where
- 2 sites in United States, Australia
- Volunteers
- 333 people
- Sponsor
- Andros Pharmaceuticals Co., Ltd.